Age 1

We help founders create longevity companies.

Longevity is at an inflection point. Due to scientific advances over the last 30 years, we are beginning to change how we interact with chronological age, living a longer number of healthy years than ever before. Here and now, we embark on this journey.

Longevity Fund is launching Age 1, a 4-month program based in SF which offers both capital and help to launch founder-driven biotechnology companies. We are selecting a small group of innovative scientists and technologists who are working to extend human healthspan to bring to San Francisco.

Team

We have started or seeded biotechnology companies with an aggregate $1B+ in market capitalization.

Navitor Pharmaceuticals
Unity Biotechnology
Precision Biosciences
Alexo Therapeutics
Metacrine
Color Genomics

Investors & Advisors

Longevity
Marc Andreessen
Felicis
Elad Gil
Founders Fund
Founders Fund

The start of something new...

Apply

Frequently Asked Questions

What's the timing of the program?

Start date: June 4, 9AM (launch meet in SF)
Calibration day: August 1, 9AM (internal presentation of interim results)
Kaplan-Meier day: October 5, 9AM (end of batch presentation to a select group of investors)

Do you provide a physical space?

We have a physical space in SF for events. There is no expectation that you work from it but it is available to you if needed.

Doesn't starting a biotech company require raising a lot of money?

Financing has been a stumbling block to founder-driven biotech companies. Should you raise from an ‘experienced’ biotech investor or from a new fund looking to get into your space, if the two are offering different terms?

We have raised >$500M for companies as either founders or involved seed investors. All of our startups have made it to the series A stage and beyond. We partner with great firms that we respect and only introduce portfolio companies to investors we trust.

What's your take on licensing?

Having a license agreement with reasonable terms is critical for an academic spinout. Knowing what royalty rates and milestones to achieve can allow you later room to negotiate with partners.

We have negotiated licensing agreements with many of the top institutions, dealt with tricky political situations, and worked with all kind of TLO requests. We can help you think about how to stage the financing while working with the TLO, down to how to cover patent costs before the deal closes.

What if I have more questions?

We're always happy to answer questions at [email protected]

How can you help with IP?

Intellectual property is at the basis of every blockbuster therapeutic. The ability to protect your drug is dependent on a well-constructed portfolio.

We have written provisionals, turned them into patents, run FTO searches, and dealt with the best and the worst in IP firms. Selecting excellent legal partners is important to a great outcome. We can help you learn to build a good IP portfolio.

What if I've never started a business?

We look to support ambitious, intelligent people who want to make an impact, regardless of whether or not they've founded a company before.

Can you help me with critical partnerships?

Yes! Partnerships can result in a non-dilutive cash infusion, but can also destroy the net value of your program. As such, we want to ensure you secure the best possible deals.

We have helped our companies source, negotiate and close milestones for >$1B in partnership value. Our mentors have lead R&D and BD at the top pharma companies in the world, and can help you efficiently connect and negotiate with partners.

What if my company is only tangentially related to longevity?

We believe the best longevity companies may actually appear to be only tangentially related to the field, so we'd love to talk.

Do I have to stay in San Francisco?

We do require companies to move to San Francisco for the duration of the 4 month program, but we then support founders wherever they choose to go afterwards. However, it is a good place to be, especially at the intersection of biology and technology.